The Journal of Heart and Lung Transplantation
Volume 29, Issue 3 , Pages 306-315 , March 2010

Changing trends in infectious disease in heart transplantation

  • François Haddad, MD

      Affiliations

    • Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford University, Stanford, California
    • Corresponding Author InformationReprint requests: François Haddad, MD, Division of Cardiovascular Medicine, Falk Cardiovascular Research Center, Stanford, CA 94305
    • ,
  • Tobias Deuse, MD, PhD

      Affiliations

    • Division of Cardiothoracic Surgery, Stanford University Medical Center, Stanford University, Stanford, California
    • ,
  • Michael Pham, MD, MPH

      Affiliations

    • Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford University, Stanford, California
    • ,
  • Prateeti Khazanie, MD, MPH

      Affiliations

    • Department of Medicine, Stanford University Medical Center, Stanford University, Stanford, California
    • ,
  • Fernando Rosso, MD

      Affiliations

    • Division of Infectious Disease, Stanford University Medical Center, Stanford University, Stanford, California
    • ,
  • Helen Luikart, RN

      Affiliations

    • Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford University, Stanford, California
    • ,
  • Hannah Valantine, MD

      Affiliations

    • Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford University, Stanford, California
    • ,
  • Sebastian Leon, MD

      Affiliations

    • Department of Medicine, Stanford University Medical Center, Stanford University, Stanford, California
    • ,
  • Thu A. Vu, BSc

      Affiliations

    • Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford University, Stanford, California
    • ,
  • Sharon A. Hunt, MD

      Affiliations

    • Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford University, Stanford, California
    • ,
  • Philip Oyer, MD, PhD

      Affiliations

    • Division of Cardiothoracic Surgery, Stanford University Medical Center, Stanford University, Stanford, California
    • ,
  • Jose G. Montoya, MD

      Affiliations

    • Division of Infectious Disease, Stanford University Medical Center, Stanford University, Stanford, California
    • Corresponding Author InformationJose G. Montoya, MD, Division of Infectious Disease, Stanford School of Medicine, Stanford, CA 94305

References 

  1. Hunt SA. Taking heart—cardiac transplantation past, present, and future. N Engl J Med. 2006;355:231–235
  2. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357:2601–2614
  3. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715–2729
  4. Hofflin JM, Potasman I, Baldwin JC, et al. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med. 1987;106:209–216
  5. Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis. 2001;33:629–640
  6. Singh N. Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis. 2003;3:156–161
  7. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am. 2003;17:113–134viii
  8. Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis. 2002;35:53–61
  9. Metzger R, Bonatti H, Sawyer R. Future trends in the treatment of serious gram-positive infections. Drugs Today (Barc). 2009;45:33–45
  10. El-Khoury J, Fishman JA. Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate-use trial. Transpl Infect Dis. 2003;5:121–125
  11. Odakowska-Jedynak U, Paczek L, Krawczyk M, et al. Resistance of gram-positive pathogens to antibiotics is a therapeutic challenge after liver transplantation: clinical experience in one center with linezolid. Transplant Proc. 2003;35:2304–2306
  12. Ortega M, Rovira M, Almela M, et al. Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol. 2005;84:40–46
  13. Viscoli C, Castagnola E. Treatment of febrile neutropenia: what is new?. Curr Opin Infect Dis. 2002;15:377–382
  14. Potena L, Holweg CT, Chin C, et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation. 2006;82:398–405
  15. Potena L, Valantine HA. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis. 2007;20:425–431
  16. Potena L, Grigioni F, Magnani G, et al. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant. 2009;28:461–467
  17. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611–620
  18. Tu W, Potena L, Stepick-Biek P, et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation. 2006;114:1608–1615
  19. Li CR, Greenberg PD, Gilbert MJ, et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 1994;83:1971–1979
  20. Krause H, Hebart H, Jahn G, et al. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant. 1997;19:1111–1116
  21. Baldanti F, Grossi P, Furione M, et al. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol. 2000;38:613–619
  22. Benden C, Aurora P, Burch M, et al. Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction. J Heart Lung Transplant. 2005;24:2103–2108
  23. Bingler MA, Feingold B, Miller SA, et al. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant. 2008;8:442–445
  24. Engelmann I, Welte T, Fuhner T, et al. Detection of Epstein-Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation. J Clin Virol. 2009;45:47–53
  25. Allen UD. Human herpesvirus type 8 infections among solid organ transplant recipients. Pediatr Transplant. 2002;6:187–192
  26. Concato C, Diociaiuti A, Parisi F, et al. Human herpesvirus-8 serology in pediatric organ transplantation. Transplant Proc. 2008;40:3683–3684
  27. Manuel O, Kumar D, Moussa G, et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation. 2009;87:719–725
  28. Clark DA. Human herpesvirus 6 and human herpesvirus 7: emerging pathogens in transplant patients. Int J Hematol. 2002;76(suppl 2):246–252
  29. Lehto JT, Halme M, Tukiainen P, et al. Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J Heart Lung Transplant. 2007;26:41–47
  30. Wade AW, McDonald AT, Acott PD, et al. Human herpes virus-6 or Epstein-Barr virus infection and acute allograft rejection in pediatric kidney transplant recipients: greater risk for immunologically naive recipients. Transplant Proc. 1998;30:2091–2093
  31. Shitrit D, Lev N, Bar-Gil-Shitrit A, et al. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int. 2005;17:658–665
  32. Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis. 1997;175:901–904
  33. Haddad F, Hunt SA, Perlroth M, et al. Pulmonary nocardiosis in a heart transplant patient: case report and review of the literature. J Heart Lung Transplant. 2007;26:93–97
  34. Peraira JR, Segovia J, Fuentes R, et al. Pulmonary nocardiosis in heart transplant recipients: treatment and outcome. Transplant Proc. 2003;35:2006–2008
  35. Arora S, Jenum PA, Aukrust P, et al. Pre-transplant Toxoplasma gondii seropositivity among heart transplant recipients is associated with an increased risk of all-cause and cardiac mortality. J Am Coll Cardiol. 2007;50:1967–1972
  36. Luft BJ, Naot Y, Araujo FG, et al. Primary and reactivated toxoplasma infection in patients with cardiac transplants (Clinical spectrum and problems in diagnosis in a defined population). Ann Intern Med. 1983;99:27–31
  37. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant. 2003;22:258–266
  38. Singh N, Limaye AP, Forrest G, et al. Late-onset invasive aspergillosis in organ transplant recipients in the current era. Med Mycol. 2006;44:445–449
  39. Bowden RA, Digel J, Reed EC, et al. Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses. J Infect Dis. 1987;156:899–903
  40. Einsele H, Hebart H, Kauffmann-Schneider C, et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 2000;25:757–763
  41. Montoya JG, Chaparro SV, Celis D, et al. Invasive aspergillosis in the setting of cardiac transplantation. Clin Infect Dis. 2003;37(suppl 3):S281–S292
  42. Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med Mycol. 2007;45:305–320
  43. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27:1266–1277
  44. Rajagopal K, Lima B, Petersen RP, et al. Infectious complications in extended criteria heart transplantation. J Heart Lung Transplant. 2008;27:1217–1221
  45. Taylor DO, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report—2008. J Heart Lung Transplant. 2008;27:943–956
  46. Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant. 2006;6:150–160
  47. Giese T, Sommerer C, Zeier M, et al. Monitoring immunosuppression with measures of NFAT decreases cancer incidence. Clin Immunol. 2009;132:305–311
  48. Konstandin MH, Sommerer C, Doesch A, et al. Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Transpl Int. 2007;20:1036–1043
  49. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006;82:663–668
  50. Rossano JW, Denfield SW, Kim JJ, et al. Assessment of the Cylex ImmuKnow cell function assay in pediatric heart transplant patients. J Heart Lung Transplant. 2009;28:26–31
  51. Teuteberg JJ, Shullo M, Zomak R, et al. Aggressive steroid weaning after cardiac transplantation is possible without the additional risk of significant rejection. Clin Transplant. 2008;22:730–737

PII: S1053-2498(09)00680-9

doi: 10.1016/j.healun.2009.08.018

The Journal of Heart and Lung Transplantation
Volume 29, Issue 3 , Pages 306-315 , March 2010

Article Tools

* Image Usage & Resolution